ArticleJournal of immunology research2026
Optimization of Erythrocyte Lysis Protocols for Robust and Reproducible T Cell Analysis in Murine Peripheral Blood, Spleen, Lung, and Bone Marrow.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimization of Erythrocyte Lysis Protocols for Robust and Reproducible T Cell Analysis in Murine Peripheral Blood, Spleen, Lung, and Bone Marrow.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Flow cytometry analysis of T lymphocytes in murine peripheral blood, spleen, lung, and bone marrow is critical for immune studies. However, inconsistent erythrocyte lysis remains a major challenge-incomplete lysis obscures lymphocyte detection, while excessive lysis damages T cells. Moreover, the variable performance of commercial lysis buffers across tissues and protocols complicates reproducibility. To address these challenges, we first established a lysis buffer that provides a relatively balanced effect on erythrocyte lysis and lymphocyte protection by systematically comparing BD, BioLegend, and Biosharp buffers in murine peripheral blood. Given the high content of red blood cells (RBCs) in peripheral blood, we used it as a screening model to identify a buffer that effectively lysed RBCs while maintaining lymphocyte integrity. The BD lysing solution demonstrated superior performance, achieving effective erythrocyte removal with 41.40% CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.